Articles tagged with Nmda Receptors
Researchers at OHSU have identified specific sites on the NMDA receptor that could potentially reverse the progression of the disease if blocked, offering new hope for treatment and early detection. The discovery was made using near-atomic imaging and raises the potential for a blood test to detect the condition.
Scientists have captured detailed images of NMDA receptors held open by natural gatekeepers and synthetic regulators, revealing how they control ion flow. This understanding can inform the design of safe and effective therapies for conditions like Alzheimer's disease and stroke.
University at Buffalo researchers capture high-resolution image of stable, open NMDA receptor, revealing kinked helices that stabilize the pore. The study expands understanding of receptor function and malfunction contributing to neurodegenerative diseases.
Researchers at MIT's Picower Institute have discovered a new approach to treating fragile X syndrome by enhancing the activity of a specific component of 'NMDA' receptors. This strategy normalizes protein synthesis, neural activity and seizure susceptibility in hippocampus of fragile X lab mice, offering a promising therapeutic target.
Ketamine has been shown to rapidly reduce depressive symptoms in patients with treatment-resistant depression, often within hours of administration. However, the long-term efficacy and safety of ketamine therapy remain uncertain, with potential risks including cognitive impairment and cardiovascular effects.
Researchers have uncovered ketamine's mechanism of action, revealing how it affects the brain's NMDA receptors. The study provides hope for synthesizing new versions of the drug with fewer harmful side effects.
The study found decreased NMDA receptors in synapses and increased extrasynaptic membranes in Alzheimer's patients, suggesting neuronal toxicity-related activity. The novel protocol allows for precise analysis of these receptors in human postmortem brains, paving the way for new therapeutic approaches.
Researchers at the University at Buffalo have identified the binding site of low-dose ketamine, revealing how it alleviates major depression symptoms within hours. The study also identifies how depression originates in the brain and may lead to further research on using ketamine-like drugs for other brain disorders.
Researchers discovered that NMDA receptors set the baseline level for neural network activity, helping maintain stable brain function. The study's findings suggest potential innovative treatments for diseases linked to disrupted neural stability.
Dumas and his team will investigate how distinct NMDA receptor domains regulate hippocampal network oscillations and spatial memory retrieval in mice with specific GluN2 subunit mutations. The study aims to identify more effective therapeutics targets for schizophrenia treatments.
Scientists at The Hospital for Sick Children discovered a molecule called LK-2 that can protect neurons during stroke and prevent brain damage. LK-2 works by blocking glutamate's binding to acid-sensing ion channels, reducing calcium flow and cell death.
Researchers found a significant reduction in serine racemase protein levels in the medial prefrontal cortex and hippocampal subfields of aged rats compared to young rats, suggesting a role in age-associated decline of NMDA receptor function. No sex differences were observed in serine racemase expression.
Researchers have developed a new weight loss drug that combines GLP-1 with molecules blocking the NMDA receptor, exploiting its effects on appetite control and neuroplasticity. This approach shows promise for greater weight loss in mice than existing medications.
Researchers investigate link between HPV vaccination and autoimmune disorder anti-NMDA receptor encephalitis. Cases associated with HPV vaccination have been reported, but underlying mechanism unclear. The study uses phylogenetic analysis of microRNA biomarkers to explore this association.
Researchers investigate how early-stage Alzheimer's disease affects memory formation by examining synaptic connections and amyloid beta. The study aims to understand the role of NMDA receptors in synaptic plasticity and how they might be hijacked by amyloid beta, leading to memory dysfunction.
Researchers discovered a striking similarity between AI models and the human brain's hippocampus, which enables powerful AI systems. By mimicking the NMDA receptor's gating process, they improved long-term memory in Transformer models.
Researchers found that enhancing NMDAR function via increased serine racemase expression improved attention and cognitive flexibility in middle-aged rats. Upregulating serine racemase in the medial prefrontal cortex also increased glutamatergic synaptic transmission, including NMDAR activity.
Researchers have developed a potential treatment for autoimmune encephalitis by creating an NMDA receptor fusion construct that neutralizes pathogenic antibodies. This innovative approach has shown promise in reducing signal transmission to neurons and may lead to improved treatment options for patients with this rare and serious disease.
Researchers have uncovered the underlying mechanism driving depressive systems in chronic pain, identifying a potential therapeutic target for treatment. Tiam1 protein modulates neural connections, leading to hypersensitivity and depression; ketamine blocks this effect, alleviating symptoms.
Researchers discovered that ketamine increases background noise, impairing the function of thalamo-cortical neurons and affecting sensory perception. This finding may contribute to a better understanding of psychosis in schizophrenia.
The study provides detailed pictures of NMDA receptors, which mediate essential signals between neurons. The findings have significant implications for treating schizophrenia, depression, and other neuropsychiatric conditions.
A team of Rutgers physicians successfully treated a 5-year-old girl with anti-NMDAR encephalitis, a rare brain disorder, using blood plasma exchanges. The treatment, which involved nearly a dozen exchanges, led to the child's full recovery, highlighting the potential for late-stage treatment.
A study reveals that four nonexcitatory amino acids can cause irreversible brain destruction after a stroke or traumatic brain injury. The amino acids flood the brain cells, leading to swelling and cell death.
A recent study from the University of Geneva suggests that ketamine's therapeutic use may be safe due to its limited impact on dopamine levels and neuronal communication. The research found that ketamine triggers a short increase in dopamine, but also inhibits a specific receptor that prevents addiction progression.
Researchers found that NYX-783, a newly discovered drug, modulates NMDA receptor activity in neurons to suppress traumatic memories and spontaneous recovery of PTSD. The drug was effective in reducing fear responses and improving treatment outcomes, particularly in female mice.
Researchers at MIT found that different types of dendrites process incoming information in distinct ways before sending it to the neuron's body. This specialization enables neurons to integrate various inputs and generate an appropriate response, particularly in navigation and planning movements.
Researchers found that astrocytes regulate cognitive flexibility by releasing D-serine and glutamate, which integrates synaptic plasticity. Heterosynaptic long-term depression is mediated by astrocytes, critical for memory modification.
Researchers have developed a new mouse model that mimics Alzheimer's neurodegeneration without relying on the pathogenic proteins amyloid or Tau. The GluN3A knockout mouse model highlights the role of calcium and neuronal hyperactivity in driving neurodegeneration, providing potential leads for new treatments and preventive strategies.
Researchers at Heidelberg University have discovered a new class of highly effective inhibitors that protect nerve cells from degeneration. The novel inhibitors target the interaction between NMDA receptors and TRPM4 proteins, which leads to cell death in neurodegenerative diseases.
Tracking each atom in the NMDA receptor has revealed how it transmits and inhibits neural signals. The discovery could lead to better treatments for Alzheimer's disease, depression, epilepsy, stroke, or schizophrenia by controlling the receptor's activity.
Researchers discovered a link between NMDA receptor dysfunction and sleep spindle deficit in schizophrenia. Medicines targeting these receptors may help treat psychiatric disorders, such as psychosis.
Researchers discovered that presynaptic PTPσ trans-synaptically regulates postsynaptic NMDA receptor responses, enabling novelty recognition in mice. Mice lacking PTPσ showed impaired social novelty recognition and failed to recognize new objects, stranger mice, and rules.
Researchers have found that autoantibodies against the NMDA receptor can reduce symptoms of depression and anxiety when they enter the brain. The level of these autoantibodies increases with age and is higher in people subjected to chronic stress, but may also play a positive role in reducing depressive symptoms.
Researchers have developed a new small molecule that potentiates synaptic NMDA receptors, restoring brain rhythms to normal patterns and improving memory in mouse models of Alzheimer's disease and Dravet syndrome. The treatment also reduced abnormal brain activity associated with these conditions.
Researchers uncover a new layer of mystery in visual memory and amblyopia by revealing NMDA receptors' unexpected role. The study shows that plasticity underlying amblyopia occurs elsewhere in the brain than previously thought.
Researchers at Johns Hopkins clarify ketamine's antidepressant properties, stating it binds to NMDA receptors rather than opioid receptors. This mechanism allows ketamine to turn off the master control switch mTOR, enabling its therapeutic effects. The FDA has approved ketamine as a nasal spray for depression treatment.
Researchers have created an animal model for a devastating autoimmune brain disease, offering new hope for diagnosis and treatment. The model allows for the specific blocking of the immune system's attack on the NMDA receptor, paving the way for targeted therapeutic strategies.
Researchers have identified a pH-sensitive pocket in the NMDA receptor that can be targeted by redesigned compounds, offering specificity for stroke and seizure treatments. The 94-series compounds show promise in preventing excessive neuronal firing without affecting healthy brain regions.
Researchers at Emory University have discovered that GluN2C is rarely paired with another subunit, challenging current understanding of NMDA receptors. This finding has implications for developing treatments for diseases such as schizophrenia and treatment-resistant depression.
Biologists at Cold Spring Harbor Laboratory have uncovered a structural variation in the NMDA receptor that enables it to function in low pH environments, such as those encountered during stroke or epileptic seizures. This adaptation could lead to new therapeutic strategies for treating neurodegenerative diseases.
Researchers at ETH Zurich have developed a marker substance to visualize NMDA receptors on nerve cells using positron emission tomography (PET). This will aid in researching various brain diseases like Alzheimer's, Parkinson's, and depression. The PET tracer may also help determine the correct dosage of drugs influencing NMDA receptor ...
Researchers have developed a new PET imaging agent that targets NMDA receptors in nerve cells to assess treatments for various neurological diseases. The agent, C-Me-NB1, provides valuable insights into the role of NMDA receptors in brain disorders.
Scientists use single-molecule FRET imaging techniques to study the dynamics of NMDA receptor gates, which control chemical signals into electrical signals. The research reveals that these gates have multiple conformational interactions that improve or degrade signaling.
Researchers at Thomas Jefferson University discovered a novel way phosphorylation affects protein function and localization, leading to increased pain sensitivity. The study offers a new target for developing alternative pain medications and provides a tool for studying synaptic development and pathology.
Neuroscientists at Tufts University have discovered a new signaling pathway that connects two major receptors in the brain associated with learning and memory. Astrocytes play a key role in regulating this pathway by sensing wakefulness and releasing chemicals that activate these receptors.
Researchers at Columbia University Irving Medical Center discovered that dysfunctional N-methyl-D-aspartate (NMDA) brain receptors cause hearing deficits in schizophrenia. Patients who received training and administration of an amino acid, D-serine, significantly improved their ability to distinguish subtle differences in pitch.
Researchers mapped the structure of a portion of the NMDA receptor, which recognizes zinc and glutamate. The study provides insight into the regulation of NMDA receptors and their role in mental health disorders.
Researchers analyzed ExAC data to explore normal variation in NMDA receptors and its link to disease-causing mutations. For some patients, this information could guide anticonvulsant treatment with repurposed Alzheimer's medication.
Researchers at UB and Johns Hopkins University discovered glutamate's crucial role in neuromuscular development, contradicting long-held assumptions. Glutamate receptors activate muscle fibers, while NMDA receptors play a key role in brain development and learning.
A study by researchers at the University of Texas M. D. Anderson Cancer Center found that gene therapy may be able to reverse cancer-related nerve pain. The treatment, which involves transferring a gene called KCC2 into the spinal canal, restored chloride levels and eliminated pain hypersensitivity in rats.
Researchers obtained images of the NMDA receptor in active, non-active, and inhibited states using x-ray crystallography and single-particle electron cryomicroscopy. The study reveals the complex movements of the receptor's subdomains during activation and provides insights into designing novel therapeutic compounds.
Researchers found that acidity can reactivate dormant N3A receptors, causing neurons to become more sensitive to glutamate, which can kill them. This finding sheds light on the role of N3A receptors in brain function and may lead to new treatments for strokes, seizures, and schizophrenia.
Researchers found structural brain damage in the hippocampus, a key memory region, that correlates with memory performance and disease severity in patients with anti-NMDA receptor encephalitis. The autoimmune disorder can cause schizophrenia-like symptoms and long-term cognitive impairment if not treated promptly.
Researchers at NIH discovered that neurons in the eye use mathematical processing to distinguish moving objects, amplifying signals through multiplicative scaling. This process may help cells determine object speed and direction.
Researchers discovered that lactate, a waste product of exercise, can protect neurons against excitotoxicity, a process that damages nerve cells after stroke or spinal cord injury. Lactate triggers the production of ATP, activating defense mechanisms that help neurons withstand overwhelming signals from NMDA receptors.
A University of Bristol study has identified the mechanisms behind disruption in brain communication channels linked to schizophrenia symptoms. The research reveals that over-activation of dopamine receptors can suppress NMDA receptor function, leading to a marked disruption of communication between key brain regions.
Researchers have discovered a neuroprotective compound that limits brain damage during ischemia associated with stroke and other brain injuries while minimizing side effects. The pH-dependent NMDA receptor antagonist, 93-31, reduces damaged brain tissue by over half in mouse models.
Scientists have obtained an atomic-level picture of the intact NMDA receptor, a massive multi-subunit complex that integrates chemical and electrical signals in the brain. The structure reveals how the receptor is regulated and offers new insight into its function, which is tightly controlled and associated with neurological diseases.
The Rett Syndrome Association of Massachusetts has donated $150,000 to support a Rettsyndrome.org approved grant to Dr. Michela Fagiolini's project at the Boston Children's Hospital. The goal is to assess NMDA receptor modulators for potential treatments in girls diagnosed with Rett syndrome.
Researchers have gained unprecedented insight into the NMDA receptor, a key player in learning and memory. The new 3D model provides vital clues for developing drugs to combat neurological diseases such as Alzheimer